Baird Medical Investment Holdings Limited (BDMD)

Healthcare · NCM

$0.75-5.61% today

Price as at 30 Sept 2026, 16:25 UTC. Quotes are delayed.

Fundamentals

Market cap$33.26M
Revenue growth (YoY)-39.0%
Profit margin-121.0%
Return on equity-77.6%
52-week range$0.66 to $3.70

Valuation and ratings

Fair value estimate$1.52
Upside to fair value+101.8%
Moat score34/100
Overall rating50/100, moderate quality

Fair value: $1.52 (+101.8%), see how we got there

Baird Medical Investment Holdings Limited trades at $0.75, which is 102% below the $1.52 our fair value estimate puts on the business. On that measure alone it screens as undervalued, though a valuation model is an argument rather than a measurement, and the market is frequently right about why something is cheap.

Our moat model scores it 34 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.

About Baird Medical Investment Holdings Limited

Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation. It sells its products through third-party distributors. It has a strategic cooperation agreement with Tianjin Yuanshan Medical Technology Co., Ltd. to focus on global development and commercialization of next-generation IRE technologies. Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.

Industry: Medical DevicesEmployees: 146HQ: China

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

BDMD passes 2 of our 30 screens today

Each screen prints the exact criteria it used, and the circumstances in which it is wrong.

BDMD peers

The largest companies in the same industry (Medical Devices), then in the same sector.

Every healthcare company we cover is on the Healthcare hub.

Common questions

Is Baird Medical Investment Holdings Limited (BDMD) undervalued?

Against our fair value estimate of $1.52, BDMD at $0.75 is 102% below fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.

Where does SteadyShares get its BDMD data?

Fundamentals for BDMD come from company filings and exchange data, as listed on NCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:25 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.

The full research page for BDMD, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.

Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.